Open Access

Molecular biomarkers for facilitating genome‑directed precision medicine in gynecological cancer (Review)

  • Authors:
    • Takeo Minaguchi
    • Ayumi Shikama
    • Azusa Akiyama
    • Toyomi Satoh
  • View Affiliations

  • Published online on: August 17, 2023     https://doi.org/10.3892/ol.2023.14012
  • Article Number: 426
  • Copyright : © Minaguchi et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Prominent recent advancements in cancer treatment include the development and clinical application of next‑­generation sequencing (NGS) technologies, alongside a diverse array of novel molecular targeting therapeutics. NGS has enabled the high‑speed and low‑cost sequencing of whole genomes in individual patients, which has opened the era of genome‑based precision medicine. The development of numerous molecular targeting agents, including anti‑VEGF antibodies, poly (ADP‑ribose) polymerase inhibitors and immune checkpoint inhibitors, have all improved the efficacy of systemic cancer therapy. Accumulating bench and translational research evidence has led to identification of various cancer‑related biomarker profiles. In particular, companion diagnostics have been developed for some of these biomarkers, which can be clinically applied and are now widely used for guiding cancer therapies. Selecting biomarkers accurately will improve therapeutic efficacy, avoid overtreatment, enable earlier diagnosis and reduce the cost of preventing and treating gynecological cancer. Therefore, biomarkers are fast becoming indispensable tools in the practice of genome‑directed precision medicine. In the present review, the current evidence of cancer‑related biomarkers in the field of gynecological oncology, their molecular interpretations and future perspectives are outlined. The aim of the present review is to provide potentially useful information for the formulation of clinical trials.
View Figures
View References

Related Articles

Journal Cover

October-2023
Volume 26 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Minaguchi T, Shikama A, Akiyama A and Satoh T: Molecular biomarkers for facilitating genome‑directed precision medicine in gynecological cancer (Review). Oncol Lett 26: 426, 2023.
APA
Minaguchi, T., Shikama, A., Akiyama, A., & Satoh, T. (2023). Molecular biomarkers for facilitating genome‑directed precision medicine in gynecological cancer (Review). Oncology Letters, 26, 426. https://doi.org/10.3892/ol.2023.14012
MLA
Minaguchi, T., Shikama, A., Akiyama, A., Satoh, T."Molecular biomarkers for facilitating genome‑directed precision medicine in gynecological cancer (Review)". Oncology Letters 26.4 (2023): 426.
Chicago
Minaguchi, T., Shikama, A., Akiyama, A., Satoh, T."Molecular biomarkers for facilitating genome‑directed precision medicine in gynecological cancer (Review)". Oncology Letters 26, no. 4 (2023): 426. https://doi.org/10.3892/ol.2023.14012